Acromegaly is a rare endocrine disordered, cause by excessive production of Growth Hormone usually by pituitary adenoma. The most common finding is the enlargement of the extremities hence the name “acromegaly”. Other findings are face distortion, cardiac problems and thicken skin. The diagnosis is confirmed with pituitary CT scan. The gold standard treatment for years is endoscopic surgery where the adenoma is removed . The most common drug class is the somatostatin analogues. Octreotide, lanreotide and pasireotide are the most effective drugs. They act by binding on the somatostatin receptors and inhibit the release of growth hormones. If there is little or no response to somatostatin analogues then other drug classes like growth hormone antagonist(pegvisomant) or dopamine agonist (cabergoline)can be added to the treatment for a most successful treatment. Growth hormone antagonist bind to the growth hormone receptor therefore decreasing the effect of the already produced and released growth hormone. Dopamine agonist binds to dopamine receptors in the pituitary and hypothalamus inhibiting the production and release of growth hormones. The newest class for treating acromegaly is the targeted secretion inhibitors. These drug is a modified botulinum neurotoxin that attacks the pituitary cells and inhibit the release of growth hormones. The least favourable treatment is the radiotherapy, where waves will damage the adenoma but it will take years for the treatment to show, if any, result.